Тедизолид - препарат нового поколения оксазолидинонов для лечения инфекций кожи и мягких тканей


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Лечение инфекций, вызванных MRSA ( Methicillin-resistant Staphylococcus aureus), остается сложной задачей, поскольку применение имеющихся в настоящее время препаратов ограничивает антибиотикорезистентность, токсичность или отсутствие пероральных лекарственных форм. В июне 2014 г. в США был зарегистрирован новый препарат группы оксазолидинонов тедизолида фосфат для лечения инфекций кожи и мягких тканей, вызванных грамположительными микроорганизмами, включая MRSA. Имеющиеся данные позволяют рассматривать тедизолид как эффективный и безопасный препарат для лечения инфекций кожи и мягких тканей, в т.ч. вызванных возбудителями, резистентными к другим антибиотикам.

Полный текст

Доступ закрыт

Об авторах

Е. А Ушкалова

РУДН

Email: eushk@yandex.ru
д.м.н., проф. кафедры общей и клинической фармакологии

Список литературы

  1. Edelsberg J., Taneja C., Zervos M., et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg. Infect. Dis. 2009; 15: 1516-18.
  2. Ray G.T., Suaya J.A., Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect. Dis. 2013; 13: 252.
  3. Shen H.N., Lu C.L. Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study. BMC Infect. Dis. 2010; 10: 151.
  4. Dukic V.M., Lauderdale D.S., Wilder J., et al. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoSOne. 2013; 8: e52722.
  5. New Antibiotic Tedizolid (Sivextro) Approved by FDA. Medscape. Jun 20, 2014.
  6. Gerson S.L., Kaplan S.L., Bruss J.B., et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 2002; 46(8): 2723-26.
  7. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 2003; 36(2): 159-68.
  8. Moran G.J., Fang E., Corey G.R., et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 2014 Jun 5. [Epub ahead of print].
  9. Urbina O., Ferrández O., Espona M., et al. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des. Devel. Ther. 2013; 7: 243-65.
  10. Ong V., Flanagan S., Fang E., et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab. Dispos. 2014; 42(8): 1275-84.
  11. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann Intern. Med. 2003; 138(2): 135-42.
  12. Colca J.R., McDonald W.G., Waldon D.J., et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. 2003; 278(24): 21972-79.
  13. Kisgen J.J., Mansour H., Unger N.R., Childs L.M. Tedizolid: a new oxazolidinone antimicrobial. Am. J. Health Syst. Pharm. 2014; 71(8): 621-33.
  14. Prokocimer P., Bien P., Deanda C., et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR 701) in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 2012; 56(9): 4608-13
  15. Im W.B., Choi S.H., Park J.Y., et al. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolid-inone antibacterial agent. Eur. J. Med. Chem. 2011; 46(4): 1027-39.
  16. Brown S.D., Traczewski M.M. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob. Agents Chemother. 2010; 54(5): 2063-69.
  17. Betriu C., Morales G., Rodríguez-Avial I., et al. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob. Agents Chemother. 2010; 54(5): 2212-15.
  18. Choi S., Im W., Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2012; 56(9): 4713-17.
  19. Prokocimer P., Bien P., Surber J., et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 2011; 55(2): 583-92.
  20. Schaadt R., Sweeney D., Shinabarger D., Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701,a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 2009; 53(8): 3236-39.
  21. Prokocimer P., Bien P., Munoz K.A., et al. Human pharmacokinetics of the prodrug TR-701 and TR-700, its active moiety, after multiple oral doses of TR-701, a novel oxazolidinone. Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington DC.
  22. Bien P., Muonz K.A., Bohn J., et al. Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic. Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington DC.
  23. Flanagan S., Fang E., Munoz K.A., et al. Single-and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid. Pharmacotherapy. 2014. Jul 3. [Epub ahead of print].
  24. Bien P., Prokocimer P., Munoz K.A., Bethune C. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects. Poster presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010, Boston,
  25. Sahre M., Sabarinath S., Grant M., et al. Skin and soft tissue concentrations of tedizolid (formerly torezol-id), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int. J. Antimicrob. Agents. 2012; 40(1): 51-4.
  26. Dreskin H., Boyea T., Barker J., Fang E., Prokocimer P. An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects. Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, IL.
  27. Dreskin H., Munoz K.A., Fang E., et al. Safety and pharmacokinetics of single oral administration of tedizolid phosphate in healthy elderly subjects and adult control subjects. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
  28. Dreskin H., Muñoz K.A., Bradley J., et al. Safety and pharmacokinetics after single oral and IV administration of tedizolid phosphate in adolescent patients. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
  29. Prokocimer P., De Anda C., Fang E., et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013; 309(6): 559-69.
  30. Bien P., Prokocimer P., Munoz K.A., Bohn J. The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic. Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases, May 16-19, 2009, Helsinki, Finland.
  31. Bradley J., Arrieta A., Capparelli E., et al. A phase 1, open-label, multi-center, single-dose, pharmacokinetic, safety and tolerance study of oral tedizolid phosphate in 12 to 17 year old patients. Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases, March 31-April 3, 2012, London, UK.
  32. Munoz K.A., Bien P., Prokocimer P. Assessment of the venous tolerability of torezolid phosphate infused via a peripheral catheter: a novel approach. Poster presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, May 7-10, 2011, Milan, Italy.
  33. Kim D., Chung H., Choi S., Im W., Rhee J. Single and repeated-dose toxicity of TR-701 (DA-7218) in rodents. Poster presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL
  34. Prokocimer P., Bien P., Munoz A., Aster R. Hematologic effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects. Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington DC.
  35. Bien P., Prokocimer P., Munoz K.A., Bohn J. The safety of 21-day multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic. Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases, May 16-19, 2009, Helsinki, Finland.
  36. Flanagan S., Bartizal K, Minassian S.L., et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob. Agents Chemother. 2013; 57(7): 3060-66.
  37. Das D., Tulkens P.M., Mehra P., et al. Tedizolidphosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin. Infect. Dis. 2014; 58(Suppl 1): S51-57.
  38. Ohlsen К. Novel Antibiotics for the Treatment of Staphylococcus aureus. Expert Rev. Clin. Pharmacol. 2009; 2(6): 661-72.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2014